Ultimovacs
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs has raised €28M across 1 funding round, most recently a Growth/Late round in Oct 2021. Based in Oslo, Norway; active in Healthtech. Data as of 28 Oct 2026.
Oslo, Norwayultimovacs.com ↗
Total raised
€28M
€27,884,496
Funding rounds
1
Investors
0
distinct backers
Active since
2021-10
latest 2021-10
Funding by year
EUR raised per yearUltimovacs — funding by year — interactive chart.
Data table
| Ultimovacs — funding by year | |
|---|---|
| 2021 | €28M |
Signals
Medium confidenceRaise-next likelihood7
base rate 37% for Growth/Late
- ▼ Dormant (no round in 3+ cohort gaps)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-26 | Growth/Late | €28M | — | View deal → |
Related news
Similar companies
same sector or country- Visma€3.0BNorway · Software
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Adevinta€1.9BNorway · Marketing
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
Global coverage: FundingData